MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
MGTX - MeiraGTx Holdings plc
$13.20
-0.39(-2.87%)7:50:00 PM 5/12/2021
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is based in New York, New York.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data
Peers

Stock news

    05/11/2021MGTX
    MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Tops Revenue Estimates

    MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -25.58% and 83.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    05/11/2021MGTX
    MeiraGTx Reports First Quarter 2021 Financial and Operational Results

    LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress. “During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology...

    05/11/2021MGTX
    MeiraGTx Holdings' (NASDAQ:MGTX) Stock Price Has Reduced 14% In The Past Year

    It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

    05/5/2021MGTX
    MeiraGTx Announces Participation at Upcoming Investor Conferences

    LONDON and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multiple conferences in May. BofA Securities 2021 Virtual Health Care ConferenceWednesday, May 12, 2021, 1:15 p.m. ET 2021 RBC Capital Markets Global Healthcare ConferenceWednesday, May 19, 2021, 4:50 p.m. ET Oppenheimer's Rare & Orphan Dis...

    04/22/2021MGTX
    MeiraGTx (MGTX) Sees Hammer Chart Pattern: Time to Buy?

    MeiraGTx Holdings (MGTX) has been struggling lately, but the selling pressure may be coming to an end soon

    04/19/2021MGTX
    MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit

    LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief development officer, will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on Monday, April 26, 2021 at 1:45 p.m. ET. A live webcast of the presentation will be available on the Inve...

    03/11/2021MGTX
    MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results

    - Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR- Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia- Completed Build of Internal cGMP Plasmid and DNA Manufacturing Facility- Strengthened Balance Sheet and Extended Cash Runway into Mid-2023- First in-vivo Data from Riboswitch Gene Regulation Platform to be Presented in 2021 LONDON and NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGT...